Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $28.82 and traded as low as $28.35. Pfizer shares last traded at $28.4050, with a volume of 35,276,356 shares changing hands.
Recent Pfizer Headlines
Here are a few of the latest headlines about PFE:
Wall Street Analyst Weigh In
A number of research firms recently issued reports on PFE. Royal Bank Of Canada raised their price target on Pfizer from $25.00 to $28.00 and gave the stock a "sector perform" rating in a report on Wednesday, November 4th. Argus set a $40.00 price objective on Pfizer in a research report on Wednesday, November 4th. Guggenheim lifted their target price on Pfizer from $31.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, November 5th. Sanford C. Bernstein reissued a "market perform" rating and issued a $29.00 target price on shares of Pfizer in a report on Thursday, November 12th. Finally, FBN Securities set a $34.00 price target on Pfizer in a research note on Friday, November 6th. Six analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $30.32.
Check Out Our Latest Stock Analysis on Pfizer
Pfizer Stock Down 1.6%
The firm has a 50 day moving average of $28.82 and a two-hundred day moving average of $27.01. The stock has a market capitalization of $161.90 billion, a PE ratio of 40.58, a P/E/G ratio of 1.90 and a beta of 0.31. The company has a current ratio of 1.42, a quick ratio of 1.10 and a debt-to-equity ratio of 0.67.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.13. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. The firm had revenue of $16.58 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the previous year, the firm posted $0.87 EPS. The company's quarterly revenue was down .4% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 3.04 earnings per share for the current year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer's payout ratio is 245.71%.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. TOWER TRUST & INVESTMENT Co grew its holdings in Pfizer by 1.9% in the third quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company's stock worth $551,000 after purchasing an additional 357 shares during the period. Angeles Wealth Management LLC increased its stake in Pfizer by 2.2% in the second quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company's stock valued at $410,000 after purchasing an additional 358 shares in the last quarter. Manchester Financial Inc. raised its holdings in shares of Pfizer by 2.9% during the second quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company's stock valued at $317,000 after purchasing an additional 365 shares during the period. Sumitomo Life Insurance Co. raised its holdings in shares of Pfizer by 0.8% during the third quarter. Sumitomo Life Insurance Co. now owns 46,503 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 371 shares during the period. Finally, Signature Equity Partners LLC boosted its position in shares of Pfizer by 22.9% during the 3rd quarter. Signature Equity Partners LLC now owns 2,067 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 385 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Company Profile
(
Get Free Report)
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company's products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.